Literature DB >> 24570922

Nutrition and metabolism in hepatocellular carcinoma.

Robert J Smith1.   

Abstract

Hepatocellular carcinoma is the fifth most common human cancer worldwide, with an overall 5-year survival in the range of 10%. In addition to the very substantial role of chronic viral hepatitis in causing hepatocellular carcinoma, nutritional status and specific nutritional factors appear to influence disease risk. This is apparent in the increased risk associated with non-alcoholic hepatic cirrhosis occurring in the context of obesity, the metabolic syndrome, and type 2 diabetes. Specific nutrients and ingested toxins, including ethanol, aflatoxin, microcystins, iron, and possibly components of red meat, also are associated with increased hepatocellular carcinoma risk. Other dietary components, including omega-3 fatty acids and branched chain amino acids, may have protective effects. Recent data further suggest that several metabolic regulatory drugs, including metformin, pioglitazone, and statins, may have the potential to decrease the risk of hepatocellular carcinoma. The available data on these nutritional and metabolic factors in causing hepatocellular carcinoma are reviewed with the goal of identifying the strength of current knowledge and directions for future investigation.

Entities:  

Keywords:  Hepatocellular carcinoma; branched-chain amino acids; metformin; obesity; statins; type 2 diabetes

Year:  2013        PMID: 24570922      PMCID: PMC3924660          DOI: 10.3978/j.issn.2304-3881.2012.11.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  62 in total

1.  Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection.

Authors:  Yu-Tse Tsan; Chang-Hsing Lee; Jung-Der Wang; Pau-Chung Chen
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544

2.  Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study.

Authors:  G A Garinis; B Fruci; A Mazza; M De Siena; S Abenavoli; E Gulletta; V Ventura; M Greco; L Abenavoli; A Belfiore
Journal:  Int J Obes (Lond)       Date:  2010-02-23       Impact factor: 5.095

Review 3.  Branched-chain amino acids as pharmacological nutrients in chronic liver disease.

Authors:  Takumi Kawaguchi; Namiki Izumi; Michael R Charlton; Michio Sata
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

4.  Iron deprivation suppresses hepatocellular carcinoma growth in experimental studies.

Authors:  Qian Ba; Miao Hao; He Huang; Junmei Hou; Shichao Ge; Zhuzhen Zhang; Jun Yin; Ruiai Chu; Hualiang Jiang; Fudi Wang; Kaixian Chen; Hong Liu; Hui Wang
Journal:  Clin Cancer Res       Date:  2011-11-03       Impact factor: 12.531

Review 5.  mTOR inhibitor for the treatment of hepatocellular carcinoma.

Authors:  Masatoshi Kudo
Journal:  Dig Dis       Date:  2011-08-09       Impact factor: 2.404

6.  Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.

Authors:  Shih-Wei Lai; Pei-Chun Chen; Kuan-Fu Liao; Chih-Hsin Muo; Cheng-Chieh Lin; Fung-Chang Sung
Journal:  Am J Gastroenterol       Date:  2011-11-15       Impact factor: 10.864

Review 7.  Statins and risk of cancer: a systematic review and metaanalysis.

Authors:  Danielle R L Browning; Richard M Martin
Journal:  Int J Cancer       Date:  2007-02-15       Impact factor: 7.396

Review 8.  Mechanisms of disease progression in nonalcoholic fatty liver disease.

Authors:  Janice Jou; Steve S Choi; Anna Mae Diehl
Journal:  Semin Liver Dis       Date:  2008-10-27       Impact factor: 6.115

9.  Hepatic protection by perioperative metabolic support?

Authors:  Mazen Hassanain; Thomas Schricker; Peter Metrakos; George Carvalho; Dionisios Vrochides; Ralph Lattermann
Journal:  Nutrition       Date:  2008-06-30       Impact factor: 4.008

10.  Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.

Authors:  Bee K Tan; Raghu Adya; Jing Chen; Syed Farhatullah; Dennis Heutling; Dan Mitchell; Hendrik Lehnert; Harpal S Randeva
Journal:  Cardiovasc Res       Date:  2009-05-04       Impact factor: 10.787

View more
  6 in total

1.  Two polymorphisms of USF1 gene (-202G>A and -844C>T) may be associated with hepatocellular carcinoma susceptibility based on a case-control study in Chinese Han population.

Authors:  Xu Zhou; Hua-qiang Zhu; Chao-qun Ma; Hong-guang Li; Fang-feng Liu; Hong Chang; Jun Lu
Journal:  Med Oncol       Date:  2014-11-01       Impact factor: 3.064

Review 2.  Nutrition and Hepatocellular Cancer.

Authors:  Kerstin Schütte; Christian Schulz; Peter Malfertheiner
Journal:  Gastrointest Tumors       Date:  2015-11-18

Review 3.  Targeting AMPK for cancer prevention and treatment.

Authors:  Weidong Li; Shakir M Saud; Matthew R Young; Guohong Chen; Baojin Hua
Journal:  Oncotarget       Date:  2015-04-10

4.  The long noncoding RNA expression profile of hepatocellular carcinoma identified by microarray analysis.

Authors:  Juanjuan Zhu; Shanshan Liu; Fuqiang Ye; Yuan Shen; Yi Tie; Jie Zhu; Yinghua Jin; Xiaofei Zheng; Yongge Wu; Hanjiang Fu
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

Review 5.  Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.

Authors:  Khanh Nguyen; Kerri Jack; Weijing Sun
Journal:  Diseases       Date:  2015-12-25

6.  Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction.

Authors:  Zhaolei Cui; Yun Li; Yanni Gao; Lingying Kong; Yingfeng Lin; Yan Chen
Journal:  Aging (Albany NY)       Date:  2020-10-09       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.